Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ANEB

Anebulo Pharmaceuticals Inc

Feb 13 • 04:00PM ET

0.4790

+0.0041 0.86 %

Healthcare • Biotechnology • USA • NASD

Feb 12, 7:19 PMAnebulo Pharmaceuticals reports fiscal Q4 2025 non-GAAP EPS of -$0.05 (+44% YoY) on zero revenue; earlier reported fiscal Q2 2026 net loss of $2.0M, cash of $9.0M with $3.0M available under a loan, and confirmed plans to file Form 25 around Feb 17 and Form 15 around Feb 27 as part of its voluntary Nasdaq delisting and deregistration.

Peers: AXSM BTAI BHVN INVA CYTK EOLS GERN EBS ELDN

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	40.54%	Shs Outstand	41.08M	Perf Week	-4.30%
Market Cap	19.68M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	24.43M	Perf Month	-56.85%
Enterprise Value	10.64M	PEG	-	EPS next Q	-	Inst Own	54.37%	Short Float	0.21%	Perf Quarter	-79.79%
Income	-7.98M	P/S	-	EPS this Y	-	Inst Trans	-9.82%	Short Ratio	0.60	Perf Half Y	-80.37%
Sales	0.00M	P/B	2.48	EPS next Y	-	ROA	-63.16%	Short Interest	0.05M	Perf YTD	-52.57%
Book/sh	0.19	P/C	2.18	EPS next 5Y	-	ROE	-69.69%	52W High	3.42 -85.99%	Perf Year	-63.98%
Cash/sh	0.22	P/FCF	-	EPS past 3/5Y	4.97% -102.33%	ROIC	-100.53%	52W Low	0.44 10.09%	Perf 3Y	-84.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.84% 11.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	23.10%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.24	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	21.20	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.24	EPS Q/Q	45.77%	SMA20	-42.89%	Beta	-0.68	Target Price	3.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-63.50%	Rel Volume	0.51	Prev Close	0.47
Employees	3	LT Debt/Eq	0.00	Earnings	Feb 12 AMC	SMA200	-74.44%	Avg Volume	83.99K	Price	0.48
IPO	May 07, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	42,534	Change	0.86%

Feb-12-26 04:15PM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates (Business Wire)
Feb-06-26 09:00AM	Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC (Business Wire) -39.05%
Jan-29-26 09:00AM	Anebulo Pharmaceuticals Announces Final Results of Tender Offer (Business Wire)
Jan-27-26 09:00AM	Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer (Business Wire) -15.73%
Dec-22-25 09:00AM	Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer (Business Wire) -20.74%
04:05PM	Loading…
Nov-13-25 04:05PM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates (Business Wire)
Sep-29-25 04:05PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates (Business Wire)
Sep-26-25 05:24AM	Anebulo begins Phase I trial of IV cannabis antidote (Clinical Trials Arena)
Sep-25-25 07:30AM	Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity (Business Wire)
Sep-12-25 07:30AM	Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives (Business Wire) +17.91%
Jul-25-25 10:51AM	Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior (GlobeNewswire)
Jul-23-25 08:00AM	Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock (Business Wire) +81.97%
May-13-25 04:05PM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire)
Feb-14-25 04:05PM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire) +9.77%
Dec-24-24 09:25AM	Anebulo Pharmaceuticals collaborates with FDA to advance selonabant (TipRanks) +29.60%
09:15AM	Loading…
Dec-23-24 09:15AM	Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise (Business Wire) +26.26%
Nov-13-24 04:05PM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates (Business Wire) -6.06%
Sep-25-24 04:05PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) -11.48% +5.95%
Jul-22-24 07:00AM	Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects (Business Wire) +9.09%
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
May-15-24 09:55PM	ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024 (InvestorPlace) -6.36%
01:05PM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire)
Feb-13-24 04:05PM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) +5.43%
Nov-14-23 04:05PM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates (Business Wire) +5.19%
Oct-19-23 09:40AM	Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year? (Zacks) +13.67%
Oct-06-23 04:06PM	Anebulo Pharmaceuticals Announces New CEO (Business Wire)
04:06PM	Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors (Business Wire)
Oct-03-23 09:40AM	Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? (Zacks)
Sep-21-23 10:06AM	Enphase Energy upgraded, Brighthouse downgraded: Wall Street's top analyst calls (The Fly)
Sep-20-23 04:29PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
08:00AM	Loading…
Aug-30-23 08:00AM	Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences (Business Wire) +6.92%
Aug-22-23 09:37AM	Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001 (Zacks) -5.83%
Aug-21-23 08:00AM	Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension (Business Wire) +10.36%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Jun-12-23 09:40AM	Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year? (Zacks) -5.66%
May-30-23 08:33AM	We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-24-23 09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-19-23 09:35AM	Down -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB) (Zacks)
May-11-23 08:00AM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates (PR Newswire)
Mar-28-23 08:00AM	Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication (PR Newswire)
Mar-08-23 08:00AM	Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions (PR Newswire) -6.33%
Feb-14-23 09:30AM	Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences (ACCESSWIRE)
Feb-10-23 08:38AM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
Jan-09-23 08:00AM	Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication (Business Wire)
Dec-21-22 05:42AM	Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth (Simply Wall St.) +15.52%
Nov-10-22 08:00AM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates (Business Wire)
Nov-01-22 04:00PM	Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors (Business Wire) +20.33% -5.52%
Sep-26-22 08:56AM	Lower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THC (Benzinga)
07:00AM	Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication (Business Wire)
07:00AM	Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing (Business Wire)
Sep-20-22 08:00AM	Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022 (Business Wire) -5.88%
Sep-09-22 08:00AM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress (Business Wire)
Aug-23-22 05:00PM	Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26 (Business Wire) -7.78% +6.37%
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
Jul-14-22 06:23AM	We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely (Simply Wall St.) -22.73%
Jul-05-22 07:57AM	Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants (Benzinga)
06:00AM	Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication (Business Wire)
Jun-23-22 04:00PM	Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022 (Business Wire) +24.41% +17.97%
May-24-22 04:00PM	Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer (Business Wire)
May-11-22 09:00AM	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates (Business Wire) -10.29%
Apr-01-22 07:00AM	Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission (Business Wire)
Feb-11-22 08:00AM	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates (Business Wire)
Feb-04-22 04:30AM	We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely (Simply Wall St.) -5.28%
Jan-06-22 07:00AM	Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference (Business Wire)
07:00AM	Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations (Business Wire)
Jan-04-22 07:00AM	Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director (Business Wire)
Jan-03-22 07:00AM	Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication (Business Wire)
Nov-12-21 08:00AM	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update (Business Wire)
Oct-13-21 08:00AM	Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose (Business Wire)
Oct-12-21 08:59AM	Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem (Benzinga)
Oct-05-21 08:00AM	Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City (Business Wire)
Sep-27-21 07:41AM	The Unintended Consequences of Ever-Increasing Marijuana Potency (Benzinga)
Sep-22-21 04:05PM	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update (Business Wire)
Sep-20-21 08:13AM	Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users (Benzinga)
Sep-13-21 08:00AM	CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication (Benzinga)
08:00AM	Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial (Business Wire)
Sep-07-21 08:00AM	Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
07:04AM	Anebulo is Developing an Antidote to Cannabis Intoxication (Benzinga)
Aug-23-21 08:31AM	Cannabis Legalization is Driving an Increase in Related ER Visits (Benzinga)
Aug-16-21 08:39AM	Alcohol, Cannabis and Synergistic Risk (Benzinga)
Aug-12-21 08:00AM	Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members (Business Wire)
Aug-09-21 08:01AM	Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year (Benzinga)
Aug-08-21 03:23AM	Here's What Anebulo Pharmaceuticals, Inc.'s (NASDAQ:ANEB) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Aug-03-21 02:40PM	The Underappreciated Risk Of Pediatric Cannabis Overdose (Benzinga) -6.17%
Jul-26-21 08:02AM	The Danger of Synthetic Cannabinoids (Benzinga)
Jul-12-21 08:22AM	The Dark Side of Cannabis Legalization and one Biotech Company's Solution (Benzinga) +5.02%
Jun-21-21 04:05PM	Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results (Business Wire)
May-06-21 08:00PM	Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering (Business Wire)

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANEB

Anebulo Pharmaceuticals Inc

Upgrade your FINVIZ experience